CZ20032635A3 - Farmaceutický prostředek na bázi anticholinergik a inhibitorů PDE-IV, způsob jeho výroby a použití - Google Patents
Farmaceutický prostředek na bázi anticholinergik a inhibitorů PDE-IV, způsob jeho výroby a použití Download PDFInfo
- Publication number
- CZ20032635A3 CZ20032635A3 CZ20032635A CZ20032635A CZ20032635A3 CZ 20032635 A3 CZ20032635 A3 CZ 20032635A3 CZ 20032635 A CZ20032635 A CZ 20032635A CZ 20032635 A CZ20032635 A CZ 20032635A CZ 20032635 A3 CZ20032635 A3 CZ 20032635A3
- Authority
- CZ
- Czechia
- Prior art keywords
- acid
- pharmaceutical composition
- inhalable
- propellant
- inhalation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10110772A DE10110772A1 (de) | 2001-03-07 | 2001-03-07 | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20032635A3 true CZ20032635A3 (cs) | 2004-09-15 |
Family
ID=7676493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20032635A CZ20032635A3 (cs) | 2001-03-07 | 2002-02-26 | Farmaceutický prostředek na bázi anticholinergik a inhibitorů PDE-IV, způsob jeho výroby a použití |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1372649B1 (enExample) |
| JP (1) | JP2004521134A (enExample) |
| KR (1) | KR20030081501A (enExample) |
| CN (1) | CN1649588A (enExample) |
| AR (1) | AR034213A1 (enExample) |
| AU (1) | AU2002257587B2 (enExample) |
| BR (1) | BR0207883A (enExample) |
| CA (1) | CA2439763C (enExample) |
| CZ (1) | CZ20032635A3 (enExample) |
| DE (1) | DE10110772A1 (enExample) |
| EA (1) | EA009989B1 (enExample) |
| HU (1) | HUP0400782A3 (enExample) |
| IL (2) | IL157326A0 (enExample) |
| MX (1) | MXPA03008045A (enExample) |
| NZ (1) | NZ528621A (enExample) |
| PL (1) | PL363078A1 (enExample) |
| TW (1) | TWI332833B (enExample) |
| WO (1) | WO2002069945A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| MXPA03010791A (es) * | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US20030235538A1 (en) | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20060189642A1 (en) * | 2003-03-28 | 2006-08-24 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| WO2004084894A1 (en) * | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases |
| SI1610787T1 (sl) * | 2003-03-28 | 2008-06-30 | Nycomed Gmbh | Sinergistična kombinacija, ki obsega roflumilastin antiholinergično sredstvo, izbrano izmed tiotropijevih soli, za zdravljenje respiratornih bolezni |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| CA2533786A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| US7071333B2 (en) | 2003-07-30 | 2006-07-04 | Bristol-Myers Squibb Company | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| EP1504756A1 (en) * | 2003-08-06 | 2005-02-09 | Kyowa Hakko Kogyo Co., Ltd | Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| CA2547394A1 (en) * | 2004-01-09 | 2005-07-28 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on a scopineester and nicotinamide derivatives |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| PT1713473E (pt) | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| EP1713472A2 (en) * | 2004-02-06 | 2006-10-25 | MEDA Pharma GmbH & Co. KG | Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids |
| WO2005082361A1 (en) * | 2004-02-27 | 2005-09-09 | Altana Pharma Ag | Roflumilast and glycopryrronium combination |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| ES2570332T3 (es) | 2005-03-16 | 2016-05-17 | Meda Pharma Gmbh & Co Kg | La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias |
| GB0521563D0 (en) | 2005-10-21 | 2005-11-30 | Glaxo Group Ltd | Novel compounds |
| NZ568349A (en) | 2005-12-21 | 2011-05-27 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| CA2749403A1 (en) | 2009-01-13 | 2010-09-02 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of syk kinase |
| WO2012025473A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
| WO2012025474A1 (en) | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Indazole compounds |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CN102670607A (zh) * | 2012-05-28 | 2012-09-19 | 海南卫康制药(潜山)有限公司 | 复方盐酸氨溴索组合物及其制备方法 |
| JP6560986B2 (ja) | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
| EP3003173B1 (en) * | 2013-05-31 | 2022-08-24 | Incipio Devices SA | Acetabular reamer assembly |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
| MY134008A (en) * | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
| WO2001057025A1 (en) * | 2000-01-31 | 2001-08-09 | Pfizer Products Inc. | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| CA2404226A1 (en) * | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| AR029984A1 (es) * | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
-
2001
- 2001-03-07 DE DE10110772A patent/DE10110772A1/de not_active Withdrawn
-
2002
- 2002-02-26 IL IL15732602A patent/IL157326A0/xx unknown
- 2002-02-26 JP JP2002569122A patent/JP2004521134A/ja active Pending
- 2002-02-26 BR BR0207883-0A patent/BR0207883A/pt not_active IP Right Cessation
- 2002-02-26 EA EA200300929A patent/EA009989B1/ru not_active IP Right Cessation
- 2002-02-26 WO PCT/EP2002/001988 patent/WO2002069945A2/de not_active Ceased
- 2002-02-26 AU AU2002257587A patent/AU2002257587B2/en not_active Ceased
- 2002-02-26 KR KR10-2003-7011716A patent/KR20030081501A/ko not_active Ceased
- 2002-02-26 PL PL02363078A patent/PL363078A1/xx not_active Application Discontinuation
- 2002-02-26 CZ CZ20032635A patent/CZ20032635A3/cs unknown
- 2002-02-26 CN CNA02805346XA patent/CN1649588A/zh active Pending
- 2002-02-26 MX MXPA03008045A patent/MXPA03008045A/es active IP Right Grant
- 2002-02-26 CA CA2439763A patent/CA2439763C/en not_active Expired - Fee Related
- 2002-02-26 HU HU0400782A patent/HUP0400782A3/hu not_active Application Discontinuation
- 2002-02-26 NZ NZ528621A patent/NZ528621A/en not_active IP Right Cessation
- 2002-02-26 EP EP02727329A patent/EP1372649B1/de not_active Expired - Lifetime
- 2002-03-06 AR ARP020100808A patent/AR034213A1/es not_active Application Discontinuation
- 2002-03-06 TW TW091104144A patent/TWI332833B/zh active
-
2003
- 2003-08-11 IL IL157326A patent/IL157326A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0207883A (pt) | 2004-07-27 |
| AU2002257587B2 (en) | 2007-05-10 |
| KR20030081501A (ko) | 2003-10-17 |
| JP2004521134A (ja) | 2004-07-15 |
| HUP0400782A3 (en) | 2012-09-28 |
| CN1649588A (zh) | 2005-08-03 |
| EA200300929A1 (ru) | 2004-04-29 |
| EP1372649A2 (de) | 2004-01-02 |
| EP1372649B1 (de) | 2012-07-25 |
| HUP0400782A2 (hu) | 2004-07-28 |
| MXPA03008045A (es) | 2003-12-04 |
| CA2439763A1 (en) | 2002-09-12 |
| IL157326A (en) | 2011-12-29 |
| DE10110772A1 (de) | 2002-09-12 |
| WO2002069945A3 (de) | 2003-01-30 |
| IL157326A0 (en) | 2004-02-19 |
| EA009989B1 (ru) | 2008-04-28 |
| NZ528621A (en) | 2005-04-29 |
| WO2002069945A2 (de) | 2002-09-12 |
| TWI332833B (en) | 2010-11-11 |
| AR034213A1 (es) | 2004-02-04 |
| CA2439763C (en) | 2012-10-16 |
| PL363078A1 (en) | 2004-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ20032635A3 (cs) | Farmaceutický prostředek na bázi anticholinergik a inhibitorů PDE-IV, způsob jeho výroby a použití | |
| US20040024007A1 (en) | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors | |
| US7776315B2 (en) | Pharmaceutical compositions based on anticholinergics and additional active ingredients | |
| US20040058950A1 (en) | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors | |
| US6608054B2 (en) | Pharmaceutical compositions based on anticholinergics and endothelin antagonists | |
| US20040019073A1 (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| US20020111363A1 (en) | Inhalable formulation of a solution containing a tiotropium salt | |
| US20040166065A1 (en) | Aerosol formulation for inhalation comprising an anticholinergic | |
| AU2003298473B2 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
| CZ20031444A3 (cs) | Farmaceutický prostředek a jeho použití jako inhalační roztok | |
| US20100310477A1 (en) | Pharmaceutical compositions based on anticholingerics and additional active ingredients | |
| CA2624786C (en) | Aerosol formulation for the inhalation of beta-agonists | |
| US20050165013A1 (en) | Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors | |
| US20090075990A1 (en) | Aerosol Formulation for Inhalation Containing an Anticholinergic Agent | |
| US20090306065A1 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
| US20090317337A1 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
| US20090170839A1 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
| CA2575385A1 (en) | Aerosol formulation for inhalation, containing an anticholinergenic agent | |
| US20090221626A1 (en) | Aerosol formulation for inhalation containing an anticholinergic agent | |
| US20030203918A1 (en) | Pharmaceutical composition comprising an anticholinergic and a heterocyclic compound | |
| CA2473815C (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| CA2492026A1 (en) | New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors | |
| ZA200306221B (en) | Novel medicament compositions on the basis of anti-cholinergics and PDE IV inhibitors. | |
| CA2430592C (en) | New pharmaceutical compositions based on anticholinergics and dopamine agonists | |
| NZ536282A (en) | Aerosol formulation for inhalation comprising a tiotropium salt |